Skip to main content
. 2022 May 25;14(11):2613. doi: 10.3390/cancers14112613

Figure 2.

Figure 2

The vicious circle of resistances to EGFR-TKI in NSCLC. Although new targeted therapies are designed to counteract the resistance mechanisms developed with previous-generation EGFR-TKI, similar resistance inevitably emerges, resulting in little improvement to overall survival in patients.